NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
Clinical Trials
14 trialsNCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn
NCT04001101 2021-11-30
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
Phase 2 Withdrawn
NCT04283526 2021-03-04
Study of Select Combinations in Adults With Myelofibrosis
Novartis
Phase 1 Withdrawn
NCT03945227 2020-10-19
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
Yonsei University
Phase 2 Withdrawn
NCT03982134 2019-10-04
PDR001 + Panobinostat for Melanoma and NSCLC
University of Iowa
Phase 1 Withdrawn
NCT02466568 2019-09-09
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT03775707 2019-05-06
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 2 Withdrawn
NCT03780634 2019-05-06
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03803254 2019-05-06
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03744247 2019-05-02
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Sun Yat-sen University
Phase 3 Withdrawn
NCT03782831 2019-05-02
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03791918 2019-05-02
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 3 Withdrawn
NCT03746249 2019-04-17
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn